Stockscreener 앱 받기
192.65
0.68%
-1.1628
전일 마감가:
$193.81
열려 있는:
$194.07
하루 거래량:
663.92K
Relative Volume:
0.34
시가총액:
$28.27B
수익:
$9.69B
순이익/손실:
$1.61B
주가수익비율:
17.57
EPS:
10.9652
순현금흐름:
$2.26B
1주 성능:
+8.90%
1개월 성능:
+2.59%
6개월 성능:
+47.31%
1년 성능:
+35.04%
1일 변동 폭
$191.03
$195.72
1주일 범위
$177.10
$202.41
52주 변동 폭
$110.03
$202.41
Biogen Inc Stock (BIIB) Company Profile
명칭
Biogen Inc
전화
(781) 464-2000
주소
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, NVS, AZN
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
192.62 | 28.44B | 9.69B | 1.61B | 2.26B | 10.97 |
|
LLY
Lilly Eli Co
|
1,034.36 | 935.00B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
239.22 | 574.95B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
224.71 | 394.59B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
NVS
Novartis Ag Adr
|
158.62 | 299.68B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
AZN
Astrazeneca Plc
|
193.68 | 291.47B | 58.07B | 9.40B | 9.87B | 3.0115 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-10 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2025-11-06 | 업그레이드 | Stifel | Hold → Buy |
| 2025-09-25 | 개시 | Jefferies | Buy |
| 2025-07-21 | 재개 | Truist | Hold |
| 2025-04-28 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-04-04 | 다운그레이드 | Argus | Buy → Hold |
| 2025-02-11 | 개시 | Bernstein | Mkt Perform |
| 2025-01-02 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-11-18 | 다운그레이드 | Needham | Buy → Hold |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-10-31 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-02-14 | 재확인 | Needham | Buy |
| 2024-02-14 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-12-20 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-12-07 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-07-24 | 재확인 | UBS | Buy |
| 2023-05-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-04-17 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-10-13 | 업그레이드 | Stifel | Hold → Buy |
| 2022-10-07 | 업그레이드 | Argus | Hold → Buy |
| 2022-09-28 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | 업그레이드 | Mizuho | Neutral → Buy |
| 2022-09-28 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | 재확인 | Barclays | Equal Weight |
| 2022-02-04 | 재확인 | BofA Securities | Neutral |
| 2022-02-04 | 재확인 | Cowen | Outperform |
| 2022-02-04 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-04 | 재확인 | Needham | Buy |
| 2022-02-04 | 재확인 | Oppenheimer | Outperform |
| 2022-02-04 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | 재확인 | Robert W. Baird | Neutral |
| 2022-02-04 | 재확인 | Wedbush | Neutral |
| 2022-02-04 | 재확인 | Wells Fargo | Equal Weight |
| 2022-02-04 | 재확인 | Wolfe Research | Peer Perform |
| 2022-01-13 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-01-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | 재개 | Raymond James | Mkt Perform |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-09-23 | 개시 | Needham | Buy |
| 2021-06-18 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | 재확인 | Truist | Buy |
| 2021-06-11 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | 업그레이드 | UBS | Neutral → Buy |
| 2021-06-08 | 업그레이드 | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | 재확인 | Barclays | Equal Weight |
| 2021-06-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2021-06-08 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-08 | 재확인 | Jefferies | Buy |
| 2021-06-08 | 재확인 | Morgan Stanley | Overweight |
| 2021-06-08 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | 재확인 | Stifel | Buy |
| 2021-06-08 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-06-07 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2021-06-07 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2021-01-29 | 업그레이드 | Stifel | Hold → Buy |
| 2020-11-10 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-11-09 | 다운그레이드 | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-11-09 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-11-09 | 재확인 | H.C. Wainwright | Buy |
| 2020-11-04 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2020-11-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-11-04 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-07-27 | 업그레이드 | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-06-22 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2020-04-23 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-01-27 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
모두보기
Biogen Inc 주식(BIIB)의 최신 뉴스
BIIB: Wedbush Raises Price Target to $187 While Maintaining Neut - GuruFocus
Mizuho Raises Price Target on Biogen to $236 From $207, Keeps Outperform Rating - marketscreener.com
Biogen Pipeline Advances In Lupus And SMA Reshape Growth Outlook - Yahoo Finance
State of Michigan Retirement System Has $6.04 Million Position in Biogen Inc. $BIIB - MarketBeat
Why Biogen (BIIB) Is Up 8.2% After Mixed 2025 Earnings and Neurology Pipeline Updates – And What's Next - Yahoo Finance
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China - ACN Newswire
Biogen Refocuses On High-Need Neurology As New Drugs Reach Inflection Point - simplywall.st
Analyst JP Morgan Raises Price Target for Biogen (BIIB) to $230 - GuruFocus
Biogen (BIIB) Sees Raised Price Target by Canaccord Genuity | BI - GuruFocus
Key facts: Analysts Boost Biogen Price Targets; Profit Outlook Improves; Leqembi Review Accelerated - TradingView
BIIB: BMO Capital Elevates Price Target While Maintaining Market Perform Rating | BIIB Stock News - GuruFocus
BIIB Analysts Maintain Rating, Significant Price Target Increase by TD Cowen | BIIB Stock News - GuruFocus
Biogen (NASDAQ:BIIB) Price Target Raised to $215.00 - MarketBeat
Biogen (BIIB) Analyst Rating Update: Citigroup Raises Price Targ - GuruFocus
Biogen Sales Execution, Growth Support Long-Term EPS, RBC Says - marketscreener.com
Guggenheim Raises Price Target on Biogen (BIIB) to $246 | BIIB S - GuruFocus
Goldman Sachs reiterates Buy rating on Biogen stock amid Leqembi growth - Investing.com
BMO Capital raises Biogen stock price target to $196 on Spinraza potential - Investing.com
BIIB: RBC Capital Increases Biogen's Price Target to $233 on Sus - GuruFocus
Biogen Posts Q4 Beat, Analysts Raise Price Targets On 'Significant Pipeline Diversification' - Benzinga
Piper Sandler Raises Price Target for Biogen (BIIB) to $177 | BI - GuruFocus
Wells Fargo Raises Biogen (BIIB) Price Target to $200 | BIIB Sto - GuruFocus
Truist Securities Raises Price Target for Biogen (BIIB) to $193 | BIIB Stock News - GuruFocus
Biogen stock price target raised to $215 from $175 at TD Cowen - Investing.com
Biogen stock price target raised to $233 from $217 at RBC Capital - Investing.com
Piper Sandler raises Biogen stock price target to $177 on Leqembi ramp - Investing.com
Biogen’s much anticipated Tau readout in Alzheimer’s will spur more questions - PharmaLive
BIIB Stock Receives Raised Price Target from HC Wainwright & Co. - GuruFocus
Wedbush Raises Price Target on Biogen to $187 From $178, Keeps Neutral Rating - marketscreener.com
Biogen’s Alisha Alaimo On The Company’s Next Big Commercial Build - Citeline News & Insights
Guggenheim raises Biogen stock price target to $246 on pipeline potential - Investing.com
Canaccord Genuity raises Biogen stock price target on strong Q4 results - Investing.com
Biogen Analysts Boost Their Forecasts After Upbeat Q4 Earnings - Benzinga
Eli Lilly To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
RBC Raises Price Target on Biogen to $233 From $217, Keeps Outperform Rating - marketscreener.com
Biogen stock price target raised to $228 from $194 at H.C. Wainwright - Investing.com
Morgan Stanley Raises Price Target on Biogen to $190 From $156, Keeps Equalweight Rating - marketscreener.com
Baird reiterates Outperform rating on Biogen stock, maintains $250 price target - Investing.com
Bernstein Adjusts Price Target on Biogen to $201 From $191, Maintains Market Perform Rating - marketscreener.com
Piper Sandler Adjusts Price Target on Biogen to $177 From $157, Maintains Neutral Rating - marketscreener.com
Citigroup Adjusts Price Target on Biogen to $215 From $185, Maintains Neutral Rating - marketscreener.com
Guggenheim Adjusts Price Target on Biogen to $246 From $185, Maintains Buy Rating - marketscreener.com
Biogen FY25 Earnings: Stable EPS, Amid Pressure From Multiple Sclerosis Franchise (BIIB) - Seeking Alpha
TD Cowen Adjusts Price Target on Biogen to $215 From $175, Maintains Buy Rating - marketscreener.com
Biogen Stock To Pop Again? China Fast-Tracks At-Home Alzheimer’s Drug Leqembi - Stocktwits
Analyst recommendations: Align, Take-Two, Biogen, PayPal, Stellantis… - marketscreener.com
The Truth About Biogen Inc: Why Everyone Is Suddenly Paying Attention - AD HOC NEWS
Biogen says biologics license application for subcutaneous formulation of Leqembi for treatment of early Alzheimer's disease designated for Priority Review in China - marketscreener.com
Biogen Says Biologics License Application For Subcutaneous Formulation Of Leqembi For Treatment Of Early Alzheimer’S Disease Designated For Priority Review In China - TradingView
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China - Biogen
Biogen Hits 52-Week High, Alzheimer's Drug Sales Jump - AOL.com
Biogen Inc (BIIB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
1.21%
자본화:
|
볼륨(24시간):